TY - JOUR
T1 - An update to the HIV-TRePS system
T2 - The development and evaluation of new global and local computational models to predict HIV treatment outcomes, with or without a genotype
AU - on behalf of the RDI Data and Study Group
AU - Revell, Andrew D.
AU - Wang, Dechao
AU - Wood, Robin
AU - Morrow, Carl
AU - Tempelman, Hugo
AU - Hamers, Raph L.
AU - Reiss, Peter
AU - van Sighem, Ard I.
AU - Nelson, Mark
AU - Montaner, Julio S.G.
AU - Lane, H. Clifford
AU - Larder, Brendan A.
AU - Harrigan, Richard
AU - de Wit, Tobias Rinke
AU - Hamers, Raph
AU - Sigaloff, Kim
AU - Agan, Brian
AU - Marconi, Vincent
AU - Wegner, Scott
AU - Sugiura, Wataru
AU - Zazzi, Maurizio
AU - Kaiser, Rolf
AU - Schuelter, Eugen
AU - Streinu-Cercel, Adrian
AU - Alvarez-Uria, Gerardo
AU - Gatell, Jose
AU - Lazzari, Elisa
AU - Gazzard, Brian
AU - Pozniak, Anton
AU - Mandalia, Sundhiya
AU - Webster, Daniel
AU - Smith, Colette
AU - Ruiz, Lidia
AU - Clotet, Bonaventura
AU - Staszewski, Schlomo
AU - Torti, Carlo
AU - Lane, Cliff
AU - Metcalf, Julie
AU - Perez-Elias, Maria Jesus
AU - Vella, Stefano
AU - Dettorre, Gabrielle
AU - Carr, Andrew
AU - Norris, Richard
AU - Hesse, Karl
AU - Vlahakis, Emanuel
AU - Barth, Roos
AU - Hoffmann, Chris
AU - Ene, Luminita
AU - Dragovic, Gordana
AU - Diaz, Ricardo
N1 - Publisher Copyright:
© The Author 2016. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved.
PY - 2016/10/1
Y1 - 2016/10/1
N2 - Objectives: Optimizing antiretroviral drug combination on an individual basis in resource-limited settings is challenging because of the limited availability of drugs and genotypic resistance testing. Here, we describe our latest computational models to predict treatment responses, with or without a genotype, and compare the potential utility of global and local models as a treatment tool for South Africa. Methods: Global random forest models were trained to predict the probability of virological response to therapy following virological failure using 29 574 treatment change episodes (TCEs) without a genotype, 3179 of which were from South Africa and were used to develop local models. In addition, 15 130 TCEs including genotypes were used to develop another set of models. The 'no-genotype' models were tested with an independent global test set (n = 1700) plus a subset from South Africa (n = 222). The genotype models were tested with 750 independent cases. Results: The global no-genotype models achieved area under the receiver-operating characteristic curve (AUC) values of 0.82 and 0.79 with the global and South African tests sets, respectively, and the South African models achieved AUCs of 0.70 and 0.79. The genotype models achieved an AUC of 0.84. The global no-genotype models identified more alternative, locally available regimens that were predicted to be effective for cases that failed their new regimen in the South African clinics than the local models. Both sets of models were significantly more accurate predictors of outcomes than genotyping with rules-based interpretation. Conclusions: These latest global models predict treatment responses accurately even without a genotype, out-performed the local South African models and have the potential to help optimize therapy, particularly in resource-limited settings.
AB - Objectives: Optimizing antiretroviral drug combination on an individual basis in resource-limited settings is challenging because of the limited availability of drugs and genotypic resistance testing. Here, we describe our latest computational models to predict treatment responses, with or without a genotype, and compare the potential utility of global and local models as a treatment tool for South Africa. Methods: Global random forest models were trained to predict the probability of virological response to therapy following virological failure using 29 574 treatment change episodes (TCEs) without a genotype, 3179 of which were from South Africa and were used to develop local models. In addition, 15 130 TCEs including genotypes were used to develop another set of models. The 'no-genotype' models were tested with an independent global test set (n = 1700) plus a subset from South Africa (n = 222). The genotype models were tested with 750 independent cases. Results: The global no-genotype models achieved area under the receiver-operating characteristic curve (AUC) values of 0.82 and 0.79 with the global and South African tests sets, respectively, and the South African models achieved AUCs of 0.70 and 0.79. The genotype models achieved an AUC of 0.84. The global no-genotype models identified more alternative, locally available regimens that were predicted to be effective for cases that failed their new regimen in the South African clinics than the local models. Both sets of models were significantly more accurate predictors of outcomes than genotyping with rules-based interpretation. Conclusions: These latest global models predict treatment responses accurately even without a genotype, out-performed the local South African models and have the potential to help optimize therapy, particularly in resource-limited settings.
UR - http://www.scopus.com/inward/record.url?scp=84994791060&partnerID=8YFLogxK
U2 - 10.1093/jac/dkw217
DO - 10.1093/jac/dkw217
M3 - Article
C2 - 27330070
AN - SCOPUS:84994791060
SN - 0305-7453
VL - 71
SP - 2928
EP - 2937
JO - Journal of Antimicrobial Chemotherapy
JF - Journal of Antimicrobial Chemotherapy
IS - 10
ER -